Evidence map›Paper›PMID 34571983›Full record

ArticleCells2021

CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production.

Juan C Garcia-Canaveras, David Heo, Sophie Trefely, John Leferovich, Chong Xu, Benjamin I Philipson, Saba Ghassemi, Michael C Milone, Edmund K Moon, Nathaniel W Snyder and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. NADCell death & disease · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Thermogenic T cells: a cell therapy for obesity?American journal of physiology. Cell physiology · 2022
    Review
  8. Review
  9. Humanized Chimeric Antigen Receptor (CAR) T cells.Journal of cancer immunology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Juan C Garcia-CanaverasDepartment of Chemistry, Princeton University, Princeton, NJ 08544, USA.ORCID 0000-0001-7112-1537
David HeoCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Sophie TrefelyA.J. Drexel Autism Institute, Drexel University, Philadelphia, PA 19140, USA.
John LeferovichCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Chong XuCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Benjamin I PhilipsonCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Saba GhassemiCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Michael C MiloneCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Edmund K MoonDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19140, USA.
Nathaniel W SnyderA.J. Drexel Autism Institute, Drexel University, Philadelphia, PA 19140, USA.
Carl H JuneCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
Joshua D RabinowitzDepartment of Chemistry, Princeton University, Princeton, NJ 08544, USA.
Roddy S O'ConnorCenter for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.
University of Pennsylvania · USPrinceton University · USDrexel University · USParker Institute for Cancer Immunotherapy · USTranslational Therapeutics (United States) · US

Funding

Directing the metabolic fate of CAR T cellsR01CA226983 · NCI · UNIVERSITY OF PENNSYLVANIA · PI JUNE, CARL H. · 2018 to 2022
$2.1M
NCI NIH HHS R01 CA226983Saint Baldrick's Foundation 587296
6 · The paper itself

Abstract

The metabolic milieu of solid tumors provides a barrier to chimeric antigen receptor (CAR) T-cell therapies. Excessive lactate or hypoxia suppresses T-cell growth, through mechanisms including NADH buildup and the depletion of oxidized metabolites. NADH is converted into NAD

Indexed as

Adenosine TriphosphateAdultAnimalsFemaleHumansLevilactobacillus brevisMaleMiceMice, Inbred NODMice, SCIDMultienzyme ComplexesNADNADH, NADPH OxidoreductasesOxidation-ReductionReceptors, Antigen, T-CellT-LymphocytesAdenosine TriphosphateMultienzyme ComplexesNADNADH, NADPH OxidoreductasesNADH oxidaseReceptors, Antigen, T-Cellarmor CAR T-cellsLactobacillus brevis NADH oxidaseLDHA

Identifiers

PMID34571983
PMCPMC8472053
OpenAlexW3197143861

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.